Tirzepatide : stands out as a product with both clinical value and innovative advantages, primarily focusing on the effective treatment of type 2 diabetes. Notably, its remarkable weight loss effects have been particularly impressive in multiple clinical trials. Its unique mechanism of action works through multiple pathways: precisely regulating blood sugar levels to stabilize metabolic balance; aiding weight management from the source by delaying gastric emptying and suppressing excessive appetite, ultimately achieving dual scientific regulation of blood sugar and weight to safeguard health.
a. High quality with competitive price
b. GMP workshop
c. Rich experience on registration
Holypharm is a professional supplier of active pharmaceutical ingredients and intermediates; agrochemicals. We are specialized in contract R&D and custom manufacturing. We have rich experience on a wide range of chemical reactions and fermentation from multi gram scale to hundred tons scale according to customers' requirement. Our entire team are passionate about delivering exceptional customer service to all of our customers. Each team member is experienced in APIs and intermediates with an abundance of ideas to help deliver effective solutions for our clients. We take our customers and consumers, our employees, society and the environment into consideration.
| Company | YT |
| Items | Specifications |
| Product Name: | tirzepatide |
| CAS number: | 2023788-19-2 |
| Purity: | 99% |
Appearance
| white power |
| function | weight loss |
| origin | origin |
Tirzepatide is a novel, once-weekly injectable glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) dual receptor agonist, developed primarily for the management of type 2 diabetes mellitus (T2DM) and approved for chronic weight management in certain patient populations. It exerts its therapeutic effects through a unique mechanism of action that targets two key incretin hormones, distinguishing it from single GLP-1 receptor agonists.
By activating GLP-1 receptors, tirzepatide enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon release from alpha cells, slows gastric emptying to reduce postprandial glucose spikes, and induces satiety to aid in weight control. Concurrently, its activation of GIP receptors further amplifies insulin secretion—particularly in response to nutrient intake—and may contribute to additional metabolic benefits, including improvements in adipose tissue distribution and lipid profiles.
In clinical trials for T2DM, tirzepatide consistently demonstrated significant reductions in glycated hemoglobin (HbA1c) levels across various doses (5 mg, 10 mg, 15 mg) compared to placebo and active comparators like semaglutide. It also showed robust weight loss effects in these trials, a secondary benefit that led to its approval for weight management in adults with obesity or overweight and at least one weight-related comorbidity (e.g., hypertension, dyslipidemia), even in the absence of T2DM. In weight management trials, patients treated with tirzepatide achieved substantial and sustained weight reduction, often exceeding that of existing weight-loss pharmacotherapies.
Pharmacokinetically, tirzepatide has a long half-life (approximately 5–7 days), supporting once-weekly administration. It is administered subcutaneously, typically in the abdomen, thigh, or upper arm, with dosage adjustments guided by therapeutic response and tolerability. Common adverse effects are gastrointestinal in nature, including nausea, diarrhea, vomiting, and constipation, which are usually mild to moderate and diminish over time as the body adjusts to the medication. Serious adverse events are rare but may include pancreatitis, gallbladder disease, or hypoglycemia (particularly when co-administered with insulin or sulfonylureas).
Beyond its approved indications, ongoing research is exploring tirzepatide’s potential in other metabolic conditions, such as non-alcoholic steatohepatitis (NASH), polycystic ovary syndrome (PCOS), and heart failure with preserved ejection fraction (HFpEF), given its favorable effects on metabolic and cardiovascular risk factors. As with all prescription medications, tirzepatide must be used under the supervision of a healthcare provider, who assesses individual patient eligibility, monitors for adverse effects, and adjusts treatment plans as needed.
-
Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide.
Tirzepatide, also known as LY 3298176, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behavior has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies reported that tirzepatide mimics the actions of natural GIP at the GIP receptor. Tirzepatide was approved for improving blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.
Appearance: Powder
Purity: >99% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
XingTai YingTai Technology Co., Ltd. is a high-tech company specializing in the research and development and production of polypeptide drugs. The company has an advanced industrial chain, covering the research and development, approval and industrialization of peptide raw materials and preparations. Its products include innovative drugs, raw materials, enzymes used in medicine and green synthesis industry, functional peptides and protein products.
Our core strengths are advanced polypeptide technology, strict quality control (conforming to cGMP standards), professional R&D team, and end-to-end solutions from raw materials to finished products.
We are committed to providing customers with high-quality and high-value products and services and have established a good reputation in the global market. With excellent product quality, logistics service and customer-centered business philosophy, our products have been exported to more than 100 countries.
XingTai YingTai Technology Co., Ltd. is willing to maintain cooperative relations with old and new friends and create a better future together
If you’re interested in our offerings, please don’t hold back from reaching out. We look forward to discussing your needs with you.
United States
Germany
Kenya
